scholarly journals Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases

2013 ◽  
Vol 27 (1) ◽  
pp. 113-127 ◽  
Author(s):  
Jennelle C Hodge ◽  
Kathryn E Pearce ◽  
Xiaoke Wang ◽  
Anne E Wiktor ◽  
Andre M Oliveira ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Experience ◽  
Renal Cell ◽  
Cytogenetic Analysis ◽  
Soft Part ◽  
Alveolar Soft Part Sarcoma ◽  
Molecular Cytogenetic

scholarly journals Dual-color, Break-apart FISH Assay on Paraffin-embedded Tissues as an Adjunct to Diagnosis of Xp11 Translocation Renal Cell Carcinoma and Alveolar Soft Part Sarcoma

2010 ◽  
Vol 34 (6) ◽  
pp. 757-766 ◽  
Author(s):  
Minghao Zhong ◽  
Patricia De Angelo ◽  
Lisa Osborne ◽  
Megan Keane-Tarchichi ◽  
Michael Goldfischer ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Soft Part ◽  
Alveolar Soft Part Sarcoma ◽  
Dual Color

scholarly journals Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma

2015 ◽  
Vol 10 (1) ◽  
Author(s):  
Dinesh Pradhan ◽  
Somak Roy ◽  
Gabriela Quiroga-Garza ◽  
Kathleen Cieply ◽  
Alyssa L. Mahaffey ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Soft Part ◽  
Alveolar Soft Part Sarcoma ◽  
Xp11.2 Translocation

Molecular cytogenetic analysis of clustered sporadic and familial renal cell carcinoma-associated 3q13∼q22 breakpoints

2002 ◽  
Vol 136 (2) ◽  
pp. 95-100 ◽  
Author(s):  
Daniëlle Bodmer ◽  
Irene Janssen ◽  
Yvonne Jonkers ◽  
Eva van den Berg ◽  
Trijnie Dijkhuizen ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cytogenetic Analysis ◽  
Molecular Cytogenetic

scholarly journals 5PSQ-224 Clinical experience of pembrolizumab with axitinib in renal cell carcinoma

2021 ◽  
Author(s):  
S Rotea ◽  
T Calleja ◽  
F Busto ◽  
M Mateos ◽  
E Fernandez ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Experience ◽  
Renal Cell

scholarly journals Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma

2011 ◽  
pp. 69
Author(s):  
Giuseppe Lombardi ◽  
Zustovich ◽  
Nicoletto ◽  
Pastorelli ◽  
Dal Bianco ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Experience ◽  
Renal Cell ◽  
Critical Evaluation

scholarly journals The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma

2017 ◽  
Vol 10 (1) ◽  
pp. 3-10 ◽  
Author(s):  
Reza Mehrazin ◽  
Essel Dulaimi ◽  
Robert G. Uzzo ◽  
Karthik Devarjan ◽  
Jianming Pei ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cytogenetic Analysis ◽  
Proportional Hazards ◽  
Proportional Hazards Model ◽  
Cox Proportional Hazards ◽  
Cox Proportional Hazards Model ◽  
Renal Tumors ◽  
Rank Test

Background: The proto-oncogene c-MYC, located on chromosome 8q, can be upregulated through gain of 8q, causing alteration in biology of renal cell carcinoma (RCC). The aim of this study was to evaluate the prevalence of c-MYC through chromosome 8q gain and to correlate findings with cancer-specific mortality (CSM), and overall survival (OS). Methods: Cytogenetic analysis by conventional or Chromosomal Genomic Microarray Analysis (CMA) was performed on 414 renal tumors. Nonclear and nonpapillary RCC were excluded. Impact of gain in chromosome 8q status on CSM, OS, and its correlation with clinicopathological variables were evaluated. CSM and OS were assessed using log-rank test and the Cox proportional hazards model. Results: A total of 297 RCC tumors with cytogenetic analysis were included. Gain of 8q was detected in 18 (6.1%) tumors (9 clear cell and 9 papillary RCC), using conventional method ( n = 11) or CMA ( n = 7). Gain of 8q was associated with higher T stage ( p < 0.001), grade ( p < 0.001), nodal involvement ( p = 0.005), and distant metastasis ( p < 0.001). No association between gain of 8q and age ( p = 0.23), sex ( p = 0.46), and Charlson comorbidity index (CCI, p = 0.59) were seen. Gain of 8q was associated with an 8.38-fold [95% confidence interval (CI), 3.83–18.34, p < 0.001] and 3.31-fold (95% CI, 1.56–7.04, p = 0.001) increase in CSM and decrease in OS, respectively, at a median follow up of 56 months. Conclusion: Chromosome 8q harbors the proto-oncogene c-MYC, which can be upregulated by gain of 8q. Our findings suggest that gain of 8q, can predict aggressive tumor phenotype and inferior survival in RCC.

scholarly journals Radiofrequency Ablation Treatment for Renal Cell Carcinoma: Early Clinical Experience

2008 ◽  
Vol 9 (4) ◽  
pp. 340 ◽  
Author(s):  
Seong-Hoon Park ◽  
Seong Kuk Yoon ◽  
Jin Han Cho ◽  
Jong Young Oh ◽  
Kyung Jin Nam ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Radiofrequency Ablation ◽  
Cell Carcinoma ◽  
Clinical Experience ◽  
Renal Cell ◽  
Early Clinical Experience
Sign in / Sign up

Export Citation Format

Share Document